Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 2-3, 2010, Pages 189-201

  Hamishehkar, Hamed ^a   Emami, Jaber ^b   Najafabadi, Abdolhossien Rouholamini ^c   Gilani, Kambiz ^c   Minaiyan, Mohsen ^b   Hassanzadeh, Kambiz ^d   Mahdavi, Hamid ^e   Koohsoltani, Maryam ^d   Nokhodchig, Ali ^f  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN POLYMER AND PETROCHEMICAL INSTITUTE   (Iran)

^f MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Controlled release; Dry powder inhalation; Insulin; PLGA; Pulmonary delivery

Indexed keywords

GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; POLYGLACTIN; RECOMBINANT HUMAN INSULIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIODEGRADABILITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; EMULSION; ENCAPSULATION; ENZYME ACTIVITY; EVAPORATION; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MEAN RESIDENCE TIME; MICROCAPSULE; NONHUMAN; PHARMACODYNAMICS; POWDER INHALER; RAT; SPRAY DRYING; STREPTOZOCIN DIABETES; SUSTAINED RELEASE FORMULATION;

ADMINISTRATION, INHALATION; ANIMALS; BLOOD GLUCOSE; CAPSULES; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HYPOGLYCEMIC AGENTS; LACTIC ACID; MALE; NEBULIZERS AND VAPORIZERS; POLYGLYCOLIC ACID; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 77951089296     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.702     Document Type: Article

References (41)

1. Choi WS, Murthy GG, Edwards DA, Langer A, Klibanov AM. Inhalation delivery of proteins from ethanol suspensions. Proc Natl Acad Sci USA 2001; 98: 11103-11107.
2. Craig CR, Stitzel RE. Modern Pharmacology. Little, Brown and Company: Boston, 1986.
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliver Rev 1996; 19: 3-36.
4. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetic Med 2003; 20: 886-898.
5. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug 2002; 19: 425-498. (Pubitemid 36314479)
6. Kawamori R. Practical concept for insulin therapy. Intern Med 1994; 73: 236-243.
7. Suarez S, Garcia-Contreras L, Sarubbi D et al. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm Res 2001; 18: 1677-1684. (Pubitemid 34020422)
8. Kwon JH, Lee BH, Lee JJ, Kim CW. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery. Eur J Pharm Sci 2004; 22: 107-116.
9. Pang Y, Sakagami M, Byron PR. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition. Eur J Pharm Sci 2005; 25: 369-378. (Pubitemid 40853864)
10. Park SH, Kwon JH, Lim SH, Park HW, Kim CW. Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. Int J Pharm 2007; 339: 205-212.
11. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871. (Pubitemid 27443665)
12. Surendrakumar K, Martyn GP, Hodgers ECM, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 2003; 91: 385-394. (Pubitemid 36980658)
13. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996; 17: 93-102.
14. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Accounts Chem Res 2000; 33: 94-101.
15. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 1999; 62: 279-287. (Pubitemid 29486508)
16. Johnson KA. Preparation of peptide and protein powders for inhalation. Adv Drug Deliver Rev 1997; 26: 3-15.
17. Hussain A, Majumder QH, Ahsan F. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res 2006; 23: 138-147. (Pubitemid 43214670)
18. Okamoto H, Aoki M, Danjo K. A novel apparatus for rat in vivo evaluation for dry powder formulations for pulmonary administration. J Pharm Sci 2000; 89: 1028-1035.
19. Emami J, Hamishehkar H, Najafabadi AR et al. A novel approach to prepare insulin-loaded poly (lactic-co-glycolic acid) microcapsules and the protein stability study. J Pharm Sci 2009; 98: 1712-1731.
20. Emami J, Hamishehkar H, Najafabadi AR et al. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 2009; 26: 1-8.
21. Enna SJ, Schanker LS. Absorption of saccharides and urea from the rat lung. Am J Physiol 1972; 222: 409-414.
22. Amidi M, Krudys KM, Snel CJ et al. Efficacy of pulmonary insulin delivery in diabetic rats: Use of a model-based approach in the evaluation of insulin powder formulations. J Control Release 2008; 127: 257-266.
23. Henderson RF, Damon EG, Henderson TR. Early damage indicators in the lung. I. Lactate dehydrogenase activity in the airways. Toxicol Appl Pharmacol 1978; 44: 291-297.
24. Codrons VR, Vanderbist F, Verbeeck RK et al. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 2003; 52: 939-950.
25. Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999; 16: 555-561. (Pubitemid 29191302)
26. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range of 0.005-15 μm. J Aerosol Sci 1986; 17: 811-825. (Pubitemid 17492310)
27. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 1994; 102: 127-132. (Pubitemid 24042986)
28. Todo H, Okamoto H, Iida K, Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm 2001; 220: 101-110. (Pubitemid 32476846)
29. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int J Pharm 1992; 88: 63-73. (Pubitemid 23000409)
30. Shen Z, Zhang Q, Wei S, Nagai T. Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations. Int J Pharm 1999; 192: 115-121. (Pubitemid 29531546)
31. Dailey G. Developing a pulmonary insulin delivery system for patients with diabetes. Clin Ther 2007; 29: 1271-1283. (Pubitemid 351172220)
32. Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077-1082. (Pubitemid 40616616)
33. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 33: 235-247.
34. Chetty DJ, Chen YW. Novel methods of insulin delivery: an update. Crit Rev Ther Drug 1998; 15: 629-670.
35. Gopalakrishnan M, Suarez S, Hickey AJ, Gobburu JVS. Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J Pharmacokinet Pharm 2005; 32: 485-500. (Pubitemid 41738437)
36. Khan MF, Gupta GSD. Cellular and biochemical indices of bronchoalveolar lavage for detection of lung injury following insult by airborne toxicants. Toxicol Lett 1991; 58: 239-255.
37. Hickey AJ, Garcia-Contreras L. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit Rev Ther Drug Carr Syst 2001; 18: 387-431. (Pubitemid 32953900)
38. Henderson RF. Use of bronchoalveolar lavage to detect lung damage. Environ Health Perspect 1984; 56: 115-129.
39. Subcommittee on Pulmonary Toxicology. Committee on Biologic Markers. Biologic Markers in Pulmonary Toxicology. National Academy Press: Washington, DC, 1989.
40. Hussain A, Yang T, Zaghloul AA, Ahsan F. Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethy-β-cyclodextrin. Pharm Res 2003; 20: 1551-1557. (Pubitemid 37268267)
41. Hara K, Tsujimoto H, Tsukada Y, Huang CC, Kawashima Y, Tsutsumi M. Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 2008; 356: 267-273.